Podiatrists in New Hampshire - Medicare Status, Address, Contact

126 Podiatrists found. Showing 121 - 126

From The Ground Up Podiatry Podiatrist Medicare: Medicare Enrolled Practice Location: 72 Portsmouth Ave, Stratham, NH 03885 Phone: 603-502-4216

James H Dolan, DPM Podiatrist - Primary Podiatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 72 Portsmouth Ave, Ste 107, Stratham, NH 03885 Phone: 603-658-0190    Fax: 603-658-0196

Dr. Tara Anne Soraghan, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 8 Clover Ln, Whitefield, NH 03598 Phone: 603-837-9005    Fax: 603-788-5072

Dr. Hal Bradley Goolman, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 8 Clover Lane, Suite 1, Whitefield, NH 03598 Phone: 603-788-2521    Fax: 603-788-5027

Azure Healthcare Services Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 10 Netherwood Rd, Windham, NH 03087 Phone: 617-953-7033

Dr. John Joseph Hammond, D.P.M. Podiatrist - Primary Podiatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 29 Mill St, Unit D5, Wolfeboro, NH 03894 Phone: 603-569-4761    Fax: 603-569-4761

News Archive

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra's drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences ("NT Life"), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

Helix BioPharma receives approval to start phase II study of topical interferon alpha-2b in low-grade cervical lesions

Helix BioPharma Corp. announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

Serum metabolite profile can help identify individuals at risk of alcohol-related disease

A new study from the University of Eastern Finland is the first in the world to show that the serum metabolite profile can be used to identify individuals likely at risk of developing an alcohol-related disease in the future.

COVID-19 patients retain immunity against the virus for at least 8 months

Australian researchers have revealed - for the first time - that people who have been infected with the COVID-19 virus have immune memory to protect against reinfection for at least eight months.

Read more Medical News

› Verified 5 days ago

• 1
• 2
• 3
• 4
• 5
• 6
• 7(current)